Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Notes Payables (2021 - 2025)

Celularity (CELU) has disclosed Notes Payables for 5 consecutive years, with $4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables changed N/A to $4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a N/A change, with the full-year FY2024 number at $3.9 million, changed N/A from a year prior.
  • Notes Payables was $4.3 million for Q3 2025 at Celularity, up from $3.9 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $37.6 million in Q4 2022 to a low of $120000.0 in Q1 2021.
  • A 5-year average of $13.4 million and a median of $4.3 million in 2025 define the central range for Notes Payables.